
Bakhos A. Tannous, PhD
@TannousLab
Followers
821
Following
2K
Media
89
Statuses
833
Executive Director, Head of Rare Cancer @AstraZeneca @Alexion Former Professor @Harvardmed Firm to find CURE for #RareCancer #GBM #DIPG #Sarcoma
Boston, MA
Joined September 2018
RT @CellCellPress: In the latest issue! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axi….
0
28
0
RT @EditorNeuro: Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with….
0
4
0
RT @NEJM_AI: Policy Corner by Abdullah H. Ishaque, MD, PhD (@ahishaque), @AbdiAidid, JD, LLM, and @gelarehzadeh, MD, PhD: Lessons from the….
0
8
0
RT @lab_gomes: Super excited to share our newest piece out today @NatureRevCancer linking age-induced metabolic reprogramming to cancer dev….
0
44
0
🟡 July is #sarcomaawarenessmonth 🟡.Sarcoma is a rare and often overlooked cancer, but its impact is deeply felt by every patient and family it touches. @AstraZeneca and @AlexionPharmaUS, we are committed to transforming outcomes for patients with rare cancers like #sarcoma
0
0
1
RT @EricTopol: The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma.https:/….
0
94
0
RT @Cancer_Cell: Online Now: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung ca….
0
33
0
I'm happy to share that I’ve started a new position as Executive Director, Head of Rare Cancer Discovery @AstraZeneca and @AlexionPharmaUS . Looking forward to what’s ahead!.
2
2
12
RT @ImmunityCP: Online now: Niche-specific therapeutic targeting of myeloid cells in the central nervous system
0
22
0
RT @gminniti2012: Good update of recommendation for LGG management in the era of vorssidenib. More trials in progress.@EANOassociation .@EO….
0
5
0
RT @DrChoueiri: “I see death’s random strikes, who it strikes, it slays and who it misses will to old age live out his days”—Zuhayr bin Abī….
0
1
0
Brain tumors don't discriminate—they impact people of all ages, backgrounds, and walks of life. At #AstraZeneca and #Alexion, we are deeply committed to advancing science and innovation in the fight against brain tumors.
0
0
1
A groundbreaking case study that may redefine GBM immunotherapy! The first report on upfront neoadjuvant administration of #immunecheckpoint inhibitors in #GBM followed by tumor resection. Patient remains recurrence-free after 17months.
0
0
1
RT @AlexionPharmaUS: We proudly stand with the rare disease community, highlighting their resilience and inspiring our continued efforts to….
0
2
0
On #RareDiseaseDay, we @AlexionPharmaUS and @AstraZeneca AstraZeneca renew our commitment to those impacted by #raredisease, especially #rarecancer. Together, we’re making a difference. 💙.#RareCancer #RareDisease #HopeInResearch #PatientCentric #AstraZeneca #Alexion
0
0
3
I had the honor of chairing the #GBM Summit in Boston where experts from patient advocacy, academia, biotech and pharma were brought together to explore advancements in GBM research and treatment. @AstraZeneca @AlexionPharmaUS #rarecancer #waragainstGBM
0
0
3
Ultrasound neurotechnologies moving quickly to the clinic, a nice review article on the use of ultrasound in different applications highlighting low-intensity focused ultrasound to open the BBB to enhance delivery of therapeutics to the brain.
Sound healing and beyond.Ultrasound neurotechnologies are moving quickly into clinical trials in a wide variety of applications, and initiatives to open-source their manufacture will make them more accessible
0
2
8
RT @NatRevDrugDisc: For readers interested in bispecific antibodies as cancer therapies, here's a comprehensive review ..
0
67
0